My point, Xena, is that the disclosure of the MTA did not mention any P2 testing prospects, which is material ... going from lab to humans is a BIG deal. Since that "deal" was not disclosed, then any movement in that direction needs another agreement or further disclosure of what is in the original agreement.
Biogen may have had just one arm of that study with a combo of their drug and 2-73. That could well explain the comment that there were things worth continued exploration in that overall failed study.
News 
Market Data 
Discover 
